Pisegna J R, de Weerth A, Huppi K, Wank S A
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Ann N Y Acad Sci. 1994 Mar 23;713:338-42. doi: 10.1111/j.1749-6632.1994.tb44086.x.
The results presented here describe for the first time the molecular cloning of the human CCKA-R. Expression of the recombinant receptor shows the expected subtype pharmacology and coupling to phosphoinositide hydrolysis reported for the native human CCKA-R. This knowledge will enhance our understanding of its distribution, pharmacology, and structure and will improve our understanding of its physiological role in the gastrointestinal and nervous systems in humans. Ultimately, this should hasten the understanding and therapy of gastrointestinal and neuropsychiatric disorders.
此处呈现的结果首次描述了人CCKA-R的分子克隆。重组受体的表达显示出预期的亚型药理学特性以及与天然人CCKA-R所报道的磷酸肌醇水解的偶联。这一知识将增进我们对其分布、药理学和结构的理解,并将改善我们对其在人类胃肠道和神经系统中的生理作用的理解。最终,这应能加速对胃肠道和神经精神疾病的理解与治疗。